Penso L, Dray-Spira R, Weill A, et al. - This nationwide cohort study draws on data from the National Health Data System to evaluate the risk of serious infection among biologics and apremilast used to treat psoriasis, with etanercept as the comparator. All adults with psoriasis who had at least 2 prescriptions for a topical vitamin D derivative in the previous 2 years and were registered in the database between January 1, 2008, and May 31, 2019, were eligible. Those who participated in the study were first-time users of biologic agents or apremilast (ie, without any prescriptions of a biologic or apremilast during the previous year). In total, 44,239 new users of biologic treatment were identified (mean [SD] age, 48.4 [13.8] years; 22 866 [51.7%] men; median follow-up, 12 months [interquartile range, 7-24 months]). In this cohort study of people with moderate to severe psoriasis, the risk of serious infections was higher in new users of infliximab and adalimumab vs etanercept, whereas ustekinumab users had a lower risk, but not new users of IL-17 and IL-23 inhibitors or apremilast. Other observational studies are required to confirm the findings for the most recent drugs.